

Docket No.: B2368C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hindley et al.

9 August 1996

Serial No: 08/458,033

Group Art Unit: 1201

Filed: December 19, 1994

Examiner: R. Gerstl

For: NOVEL COMPOUNDS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 09 1996

MATRIX CUSTOMER
SERVICE CENTER

SUPPLEMENTAL AMENDMENT AND REQUEST THAT AN
INTERFERENCE BE DECLARED UNDER RULE 607

Sir:

Further to the response submitted June 21, 1996, please amend this application as follows:

AMENDMENT

IN THE CLAIMS:

Please add claims 14 and 15 as follows:

-- 14. A method of treating impaired glucose tolerance comprising administering to a host suffering therefrom a therapeutically effective amount of a compound selected from the group consisting of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione and 5-(4-(2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione.

15. The method of claim 14, wherein the compound is 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione.--